VigiLanz Ranked No. 1 by KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance for Fourth Straight Year

The clinical surveillance company most trusted by hospitals is recognized as Best in KLAS, totaling 10 KLAS awards over 4 consecutive years

MINNEAPOLIS – Feb. 2, 2021 – VigiLanz, a clinical surveillance company, today announced that it has earned 2021 Best in KLAS designations from KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance. This is the fourth year VigiLanz has been recognized by KLAS as a leader across both areas, and brings its total count of KLAS awards to 10. VigiLanz was also recognized in previous years in the Antimicrobial Stewardship category, which KLAS folded into Pharmacy Surveillance this year.

VigiLanz products earned Best in KLAS across two segments in the “2021 Best in KLAS: Software and Services” report, released on February 2:

Infection Control and Monitoring

Earning a score of 93.7, VigiLanz’s Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s EHR. Its exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“VigiLanz has been really good through the COVID-19 crisis because every time we need a new test, I just email the vendor, and they add it to the product. The vendor’s help has been a blessing.”

  • Physician, August 2020, klasresearch.com

Pharmacy Surveillance

Earning a score of 91.1, VigiLanz’s Dynamic PharmacoVigilance product acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for adverse drug event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“The product is extremely easy to use, and that has to be a big part of our success. Something that is hard to use or clunky wouldn’t work for our teams’ workflow. It doesn’t matter how good the quality of the material is; a clunky product wouldn’t work because we are moving at such a fast pace.

  • Manager, June 2020, klasresearch.com

In addition, VigiLanz’s Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, drug-bug mismatches, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and is certified by the National Healthcare Safety Network for easy, direct reporting on antibiotic use.

“I have found VigiLanz to be really helpful with their ability to fine-tune a rule and screen out a lot of noise. So we are getting exactly what we need. We can tease out geography, look at specific organisms, or look at different time frames. This is very powerful and very easy to do in the system.”

  • Director, January 2020, klasresearch.com

“In what’s proven to be a particularly challenging year for our hospital customers, we’re extremely proud to continue our recognition by KLAS four years in a row,” said VigiLanz Chairman and CEO David Goldsteen, MD. “We know our customers rely on us when they need it most—whether that’s triaging COVID-19 cases, monitoring the use of specific pharmaceuticals during a shortage, or saving clinicians time providing real-time alerts and reports so they can focus more on patients. It’s our job to help hospitals keep patients safe, and we’re honored to see the glowing feedback from this past year.”

Best in KLAS is a recognition given to vendors for outstanding efforts to help healthcare professionals deliver better patient care. The Best in KLAS designation is reserved for the software and services market segments that have the broadest operational and clinical impact on healthcare organizations. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

Selected commentary collected about VigiLanz Infection Control and Monitoring and Pharmacy Surveillance, January 2021  © 2021 KLAS. Visit klasresearch.com for a complete view.

###

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

Vigilanz Offers COVID-19 Vaccine Management Solution Free to Customers | Healthcare IT Today

VigiLanz, a clinical surveillance company, announced the launch of a new mass vaccination support software. The company is offering Vigilanz Vaccinate free to its existing customers to help frontline healthcare teams stay safe.

I had the chance to sit down with Stacy Pur, Vice President of Product Development at Vigilanz to find out more about their product and to talk through some of the unique challenges of these early vaccines.

Why Free?

“The COVID-19 issue is personal—at VigiLanz, we have had employees and family members contract COVID-19 and require medical intervention,” said David Goldsteen, VigiLanz’s CEO. “We are so grateful for the amazing care healthcare teams are delivering across the country, and we wanted to do something to help. It was important to us to offer this tool [Vigilanz Vaccinate] to current customers for free to help them and their frontline healthcare teams stay safe during this extremely challenging global pandemic. It’s the right thing to do.”

You can read more of this article on Healthcare IT Today.

Hospital Patient Safety Report: Infection Prevention Findings

To better understand the state of hospital patient safety and the biggest opportunities for improvement, VigiLanz commissioned Sage Growth Partners, a healthcare consultancy, to conduct an independent survey of 100 hospital and health system leaders in February 2020.

View the full report here.

This infographic highlights some of the most noteworthy infection prevention-related survey findings. The infographic reveals:

  • How hospital leaders rate their infection prevention efforts
  • Where infection prevention falls on their list of top safety priorities
  • How they are using technology to support their efforts

Economic Value Tool – Calculate Your Savings

Healthier Patients, Healthier Bottom Line

Calculate Your Savings
See how your hospital or health system could be using VigiLanz to save millions by optimizing efficiency and improving patient safety.

VigiLanz leads to savings throughout your health system—from the pharmacy department, to infection prevention, to overall quality and safety.

We’ve designed this calculator to provide insight into VigiLanz’s high economic impact. VigiLanz improves workflow and staffing efficiency, reduces and prevents costly safety errors and adverse events, and identifies cost-savings opportunities such as IV to PO conversions.

The tool starts with national benchmark data, but allows you to enter your own organization’s information for a more customized analysis. See your hospital’s potential savings in key areas, plus, receive a full report to see hospital-wide savings and a detailed description of the key savings drivers and methodology.

VigiLanz Launches COVID Quick Start, a Respiratory Viral Illness Prevention Software, Partnering with Datica for Rapid Deployment

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months

MINNEAPOLIS – May 20, 2020 – VigiLanz, a clinical surveillance company, today announced COVID Quick Start – a new solution that will enable hospitals to prepare for, prevent, and respond to the spread of COVID-19 and other respiratory viral illnesses. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Partnering with Datica for rapid deployment and supported by a team of VigiLanz’s certified infection preventionists, the software is designed to alleviate the burden on hospital IT resources and clinical staff while increasing patient safety. The solution is available for free for the first six months, with flexible financing options thereafter.

Learn more

COVID Quick Start uses VigiLanz’s clinical surveillance platform to help hospitals adapt to the evolving conditions associated with respiratory viral illnesses. The platform continuously pulls patient data from a variety of sources, including EHRs, and evaluates that data against rules that issue real-time alerts to clinical staff. The rules are designed to identify potential respiratory viral illnesses, ensuring early isolation and management of patients, and can also track disease clusters to identify local outbreaks and hospital acquisition.

“Our team recognized that VigiLanz’s software and expertise could be tailored to address the unique issues presented by this pandemic and other potential respiratory viral illnesses, and that we could design a solution with a low barrier to entry,” said Stacy Pur, Vice President of Product Development at VigiLanz. “We’ve built COVID Quick Start as a solution that works both for hospitals with well-funded infection prevention programs, and those where resources may be more restricted. These organizations are facing a possible second wave of COVID-19 on top of the upcoming influenza season. Our Quick Start solution, which provides the basics of what hospitals need to monitor – such as exposures, early case identification, COVID-19 state and federal reporting requirements, and isolation – will help hospitals quickly prepare for what is coming.”

Recognizing the urgency for hospitals to have a solution like this in place, COVID Quick Start uses VigiLanz Connect, an API solution for hospital EHRs, powered by Datica, to deliver an even faster integration. This solution minimizes the burden on hospital IT resources and enables COVID Quick Start to begin improving patient safety as quickly as possible.

“Datica has deep expertise, with over 400 successful EHR integrations,” said Dave Levin, MD, Chief Medical Officer at Datica. “We’re proud to collaborate with VigiLanz as their EHR integration partner to quickly launch their COVID Quick Start product.”

COVID Quick Start provides an easy and low-risk entry to the full suite of VigiLanz’s SaaS-based clinical surveillance solutions. VigiLanz helps health systems avoid or minimize harm, optimize clinical outcomes, and support preventive care by aggregating and monitoring disparate data in real time from across the EHR and other health system databases. VigiLanz was ranked No. 1 by KLAS Research this year across three categories – Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the third year in a row it has earned Category Leader designations from KLAS.

Learn more about COVID Quick Start at vigilanzcorp.com/covid-19/.

 

###

 

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

About Datica

Datica is the only managed service provider (MSP) that solves healthcare’s biggest roadblocks–EHR integration and cloud compliance. Its integration solution enables data integration from any source, to any destination, in any format – without sacrificing PHI security. Datica’s cloud compliance solution offers end-to-end managed services for digital innovators to scale rapidly in the cloud, while ensuring HIPAA compliance and HITRUST certification are in place.

With over 400 live integrations and compliant cloud infrastructure for Fortune 500 companies, Datica’s deep expertise gives you the confidence and infrastructure to scale quickly and securely. For more info, visit: https://datica.com.

 

A Message from David Goldsteen, MD, VigiLanz CEO


To our hospital partners and healthcare providers,

Thank you for the long hours you are working, the risks you are taking, and the sacrifices you are making to care for patients with COVID-19. VigiLanz is here to support you in any way that we can.

Over the past few weeks, you’ve shared some of your top challenges with us. We’ve also gathered insights from our internal clinical team. Based on these discussions, we’re enabling new COVID-19 related rules, reports, and alerts almost daily and supporting custom requests based on the unique needs of each hospital.

We’ve also created a new COVID-19 Testing Results report. This report compiles all patients with a COVID-19 order, positive/negative lab result, or positive microbiology report. In addition, it includes patient demographics, clinical parameters like temperature, SpO2, FiO2, medications, and discharge disposition. As with all of our reports, it can be exported to Excel after it’s generated.

As the COVID-19 crisis evolves and your needs change, we will continue to reach out and identify new ways to help. We’ll share that information here, on our website, and in emails.

In the meantime, please let us know if there are any other ways we can support you.

With gratitude for the important work you’re doing.

David

David Goldsteen, MD, MBA
Chairman & CEO, VigiLanz

COVID-19 Rules and Solutions

Updated April 7, 2020

Hospitals across the country are reaching out to us with requests for clinical surveillance support related to COVID-19. We’re responding by creating new rules, alerts, and reports on an almost daily basis.

To ensure you are aware of these resources available to you, we’ve assembled the two below lists:

  • List 1 is a compilation of the rules, alerts, and reports that are currently available.
  • List 2 is a compilation of the rules, alerts, and reports that are available to your hospital by request. These have been implemented at other hospitals based on their unique needs and challenges.

We update these lists regularly by posting the newest rules at the top.

 


List 1: Rules, alerts, and reports currently available

Infection prevention:

  • Syndromic screening for COVID-like illnesses (monitoring of vitals, imaging, and notes to identify possible patients who have not tested positive, yet need to be isolated)
  • Alerts for all who have testing ordered, as well as patients who have tested positive and negative
  • Alerts to identify patients who are at high risk and alerts to identify disease clusters
  • Rules and alerts to identify patients missed through all other means of screening and identification, i.e. leveraging ICD-10 billing codes specific to COVID-19
  • Reports to gauge the COVID-19 burden on the hospital (including data on admissions, testing, ICU utilization, ventilator utilization, and medication utilization)
  • Tools to work up employee exposures, furlough needs, testing, and disease acquisition
  • Tools that streamline reporting to public health partners. NHSN recently introduced a COVID-19 Patient Impact and Hospital Capacity Module within its Patient Safety Component. We are developing an on-demand report that includes the requested information, such as daily counts of confirmed and suspected COVID-19 patients and use and availability of beds and ventilators.

Pharmacy surveillance:

  • *NEW* Customer webinars:
    • Pharmacy Module: COVID-19 Rules and Report
      Thursday, April 9, 2020
      2:00PM- 2:20 PM CTThis webcast presentation will review potential rules around COVID-19 and a new Ad Hoc report built to identify COVID-19 patients. Register here.
    • Pharmacy Module: Managing Drug Shortages
      Tuesday, April 14th, 2020
      10:30AM-11:00 AM CTThis webcast will present all the tools within VigiLanz to effectively to manage a drug shortage. Register here.
  • Alerts when specific medications are ordered to help limit their use (and ensure the proactive identification of patients on medications that may be in short supply due to COVID-19)
  • Alerts when patients on medications that are in short supply could be switched to alternative therapies
  • Real-time reports that identify patients with active orders for particular drugs
  • Immediate notification to staff related to drug shortages and the process for handling certain drugs by using the Client Communication Tool on the VigiLanz home/landing page

In addition, we’ve created a new COVID-19 Testing Results report that can help all of your hospital’s relevant healthcare providers better care for COVID-19 patients. This report compiles all patients with a COVID-19 order, positive/negative lab result, or positive microbiology report. In addition, it includes patient demographics, clinical parameters like temperature, SpO2, FiO2, medications, and discharge disposition. As with all of our reports, it can be exported to Excel after it’s generated.

 


List 2: COVID-19 rules, alerts, and reports available by request

Please note – these can be enabled based on your individual needs, and on the data feeds that are available at your site. Please submit an IssueTrak ticket for customized support.

Infection prevention:

  • Alerts when COVID-19 patients are readmitted
  • Alerts when patients have been discharged but test positive
  • Alerts when COVID-19 patients are discharged
  • Line list reports
  • Vented patient reports
  • COVID-19 patients that need ventilators reports
  • Expired COVID-19 patients reports
  • Total positives over time reports
  • Identify inpatients who are being prescribed inhalers but who are not under isolation

Pharmacy surveillance:

  • COVID-19 treatment ordered: remdesivir, hydroxychloroquine, chloroquine, darunavir, lopinavir, tocilizumab
  • Inhalers ordered for patients not on isolation
  • Nebulized meds ordered for COVID-19-positive patients
  • Prolonged QTc with hydroxychloroquine +/- azithromycin
  • Missing baseline QTc with hydroxychloroquine
  • Reports for a daily review of meds to minimize the number of admins/day (minimize PPE consumption)
  • Support daily medication reviews by pharmacists to minimize the number of required clinician contacts with suspected or known positive COVID-19 patients

VigiLanz Ranked No. 1 by KLAS Research Across Three Categories for the Third Year

Clinical surveillance company recognized again as a KLAS leader in antimicrobial stewardship, infection control and monitoring, and pharmacy surveillance

 

MINNEAPOLIS – Feb. 4, 2020 – VigiLanz, a clinical surveillance company, today announced that it has earned 2020 Category Leader designations from KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the second year VigiLanz has been recognized by KLAS as a Category Leader across all three areas, and the third year to earn that distinction in Infection Control and Monitoring and Pharmacy Surveillance, prior to the Antimicrobial Stewardship category being added in 2019.

Three VigiLanz products were recognized in the “2020 Best in KLAS: Software and Services” report, released on January 31:

VigiLanz Dynamic Infection Control Monitor

Earning a score of 92.7, the Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s EHR. Its automatic exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“I really like the ability to adapt the rules in Dynamic Infection Control Monitor. Interpreting rules is much easier now than it was with our last system. My infection control team is not super tech savvy, and my people have other tasks and jobs to worry about. The system makes doing their jobs easy for them.”

  • Manager, August 2019, klasresearch.com  

VigiLanz Dynamic PharmacoVigilance

Earning a score of 92.8, Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“The versatility of the VigiLanz system is its strength. We have been able to leverage rule abilities on many fronts. The product is excellent. It does a great job with tasking and the workflow of identifying patients. The product is very robust.”

  • Analyst/Coordinator, August 2019, com

VigiLanz Antimicrobial Stewardship

Earning a score of 93.3, the Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, drug-bug mismatches, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and provides direct reporting to the Centers for Disease Control’s National Healthcare Safety Network.

“VigiLanz doesn’t provide software where we have to fill in the blanks. The software has a framework that allows us to create our own world. The software is limitless. In this ever-changing world, the VigiLanz product is what we need for healthcare.”

  • Director, November 2019, klasresearch.com

“Our customers’ trust in our clinical surveillance products is the highest level of affirmation we can achieve,” said VigiLanz Chairman and CEO David Goldsteen, MD. “We strive to exceed our customers’ expectations year over year. We are proud to be recognized as a Category Leader for three years running. To the customers who asserted their confidence in us and our products – thank you. We will continue to set the bar higher and support you in building healthier hospitals.”

The KLAS Category Leader designation is awarded to vendors that lead select market segments in which at least two products meet a minimum number of KLAS Konfidence reviews. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

 

###

 

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

 

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

My Favorite VigiLanz Rule: Pharmacists and IPs Share Their Top Picks

At VigiLanz, data rules! And as a VigiLanz customer, you can create more actionable data by tapping into our extensive rules library or creating new rules based on your unique needs. Our clinical experts are always standing by to help, whether you need help adjusting an existing rule or creating something new.

We’ve gathered some inspiration from real VigiLanz customers on their favorite and unique VigiLanz rules that have a significant impact on patient care.

 


Biofire Alert

Jeremy Frens, PharmD, BCPS-AQID, Antibiotic Stewardship Coordinator at Cone Health

“My favorite rule is the positive Biofire alert. We have customized the alert so that our antimicrobial stewardship team and ID physicians get email or text alerts based on the organism detected. Our hospital has a policy that an ID physician sees patients with Staph aureus, Candida, or enterococcal bacteremia. With the text or email alerts going directly to them, they can respond quickly, often the same day as the alert. We feel that this process helps to streamline antibiotics more quickly!”


High Risk C. difficile

Erica Lawrence, MSN, RN, Infection Preventionist at Virginia Mason Medical Center

“My favorite one is the high risk C. difficile rule. This rule helps to alert us proactively of patients at risk for C. difficile, but not necessarily diagnosed or symptomatic with C. diff. This allows for the AMS group to review prescribed medications and make recommendations to the providers if de-escalation of antibiotics or gastric acid suppressors is appropriate. Another intervention is adding signs and symptoms of C. difficile to the discharge instructions to ensure patients are educated about when to follow up with their provider if signs and symptoms of C. difficile begin after discharge.”


Critical Medication Discontinued

Jill Bennett, PharmD, APh, BCPS, Clinical Pharmacy Coordinator at Antelope Valley Hospital

“Some of my favorite rules are the ones that alert us to medications that have been discontinued when that might be detrimental to a patient outcome. For example: Levetiracetam DC’d and no active anticonvulsant order, or in patients with prolonged LOS when routine medications may fall off the profile from an ASO: Inpatient Day #30 – Check Med Profile. The real-time culture info is also nice.”


Patient Discharge SNF

Chrissie Wiebe, Infection Preventionist at Maury Regional Medical Center

“I would have to say my favorite rule we have is the “Pt Discharge SNF (CMP-QI Grant Locations)”. I like this rule because we are able to track patients who are going to certain nursing homes at discharge using keywords in their documentation. This rule is helpful because we have a grant that is allowing us to work with certain local nursing homes to help prevent readmission. This rule allows us to know which patients are going to these locations so we can get a better idea as to where our patients are going and how we can best serve the SNF’s in order to prevent a possible readmission for something they can take care of at their facility.”


Highly Infectious Disease Email Alerts

Jordan Ehni, CIC, MPH, Systems Integration Infection Preventionist at Mount Sinai Health System

“I think my favorite rule/function are the email alerts that we can set up for when a patient with a highly infectious disease comes into the hospital. We don’t have time to constantly check VigiLanz throughout the workday, so it is good to know we have this ‘back up’ alert if we go a few hours between checking our Isolation Bucket.”


Highly Infectious Disease Email Alerts

Sarah Lowtharp, MSN, RN, CIC, Assistant Director of Infection Prevention at St. Bernards Medical Center

“My favorite rules are centered on alerting us of highly infectious patients immediately. I get an email alert from a rule trigger in VigiLanz on possible meningitis, possible TB, CROs, and possible Candida auris (the Candida isolates we are required to send to dept. of health for auris testing). I usually receive my email/VigiLanz alert before our own lab notifies us of these scenarios.”

 


Real-Time Blood Culture Contamination Results

Frank Vanskike, MPH, CIC, Infection Preventionist at Phoenix Children’s

“We worked with our VigiLanz team to build a rule around blood culture contamination results in our ED. These reports alerted us in real-time as opposed to the previous method where we were provided the contamination rate at the end of the month. We were able to build a report off of the rule and disseminate to the ED and stakeholders on a weekly basis. This intervention helped us track when and where contamination on blood draws were occurring so real-time education and feedback could be provided. Furthermore, this helped the ED because the report enabled us to communicate to the ED patients that had contaminated specimens that were not true infections and did not need to return to the ED to seek treatment. This saved a return visit to the hospital for families, avoided potential readmissions, prevented unnecessary antibiotic use, and eliminated unnecessary financial costs.”

 


Metabolic Support Consult for ICU & Ventilator Patients

Adrienne Carey, PharmD, BCPS, Clinical Pharmacist / Data Mining Program Manager at Freeman

“We created a group of rules to alert our Metabolic Support Team to the fact that a patient in our ICU is on a ventilator and may need a metabolic support consult for enteral or parenteral nutrition management. A metabolic support consult can sometimes get overlooked in these patients since at the time of admission they do not have an immediate need for nutritional support and no order for such is entered by a physician, but these patients still need to be monitored closely as after a period of time on sedation, they will need nutritional support. Our Metabolic Support Team is alerted to about 30 patients per month with these rules.”

Top Five Tasks Infection Preventionists Need to Prioritize in 2020

The more you plan and prepare, the safer your patients will be. Here’s advice from our clinical team members. 

As the New Year begins, it’s critical for infection preventionists to begin thinking about—and preparing for—the year ahead. The more you can plan and prepare, the safer your patients will be. Here are the top five tasks (in no particular order) that our clinical team members say all infection preventionists need to prioritize over the next few months:

1.  Continue monitoring re-emerging diseases such as measles and mumps.

Recent outbreaks of measles have resulted in the largest number of confirmed measles cases the U.S. has seen in 25 years, according to the CDC. Mumps is also a problem, with 48 states reporting mumps infections in 2,618 people between January 1, 2019 and October 11, 2019.

Since screening for measles and other reemerging diseases often requires specialized testing, and there can be delays in receiving positive results from off-site labs, you must have a surveillance tool in place that can assist with identifying patients that may be symptomatic, rather than waiting on the final results. That way you can respond as quickly as possible.

At APIC 2019, Jennifer Boe, BSN, RN, PHN, CIC, an infection preventionist at Children’s Minnesota, shared how she and her colleagues used VigiLanz’s clinical surveillance technology to help quell a measles outbreak in their community in 2017. “We worked with our VigiLanz support team member to create a new rule, which alerted us whenever a measles test was ordered,” said Boe. “… Knowing about suspect cases ahead of time ensured we were in the loop, and it allowed us to identify potential exposures so we could rapidly respond if the measles test was positive.”

2.  Stay on top of emerging pathogens and outbreaks.

While it’s critical to monitor re-emerging diseases, it’s also important to watch for newly emerging problems. Another serious outbreak, such as Ebola, for example, could occur at any time here in the United States.

You must closely monitor your patient population for any problems and ensure you have tools in place that will flag potential problems in real time. Also, make sure you have a plan so that if a problem does arise, you can respond as quickly as possible (such as by isolating patients as soon as a test is ordered, rather than waiting for a positive result).

3.  Monitor the spread of MDROs, such as Candida auris, and heighten your prevention efforts.

In 2013, the CDC estimated that 23,000 people a year die as a result of antibiotic-resistant germs; it recently nearly doubled that figure to 44,000 deaths.

We don’t need to tell you what a serious problem MDROs represents, but we can’t stress enough how critical it is to closely monitor your patient population. You must ensure you have a flexible and robust surveillance tool that can assist in the identification of at-risk, exposed, and infected patients in real time. The faster you can respond to these issues, the safer your patients will be.

4.  Watch for NHSN changes impacting surveillance.

Every year, NHSN makes changes to its patient safety definitions. You can find a summary of the 2020 NHSN changes here. You must have a clinical surveillance platform that is ready to implement those changes at the start of 2020 so that the transition is seamless. At VigiLanz, we’re proud of our ability to quickly adapt and implement changes into our system based on new requirements and your healthcare system’s unique needs.

For example, at the very beginning of the New Year, we revised our CLABSI rules to account for the 12 organisms NHSN added as commensal organisms. We’re also ready to start allowing our users to report on HAI and LABID events via our file submissions. We will provide a more in-depth summary of the changes we’ve made to accommodate the 2020 updates from NHSN in our upcoming customer newsletter.

5.  Improve efficiency related to identifying, documenting, and preventing risks.

Identifying potential problems related to the care environment, equipment cleaning, and sterilization, requires frequent rounding and the ability to quickly compile and disseminate your findings to stakeholders who can remediate the problems. 

VigiLanz enables you to use real-time rounding tools to more efficiently document and monitor isolation compliance, hand hygiene, ICRAs, and EOCs. This ensures problems are addressed sooner, and it enables you to spend more time focusing on direct patient care.

If you already have VigiLanz in place, consider streamlining your rules so that only actionable items appear in the workflow (your clinical support team member would be happy to assist with this). Reducing the number of activations that are being created because they are nice to have, rather than needed, will reduce the time you spend working through lists.

To learn more about how to use VigiLanz to accomplish these tasks and ensure a safer 2020 for your patients, contact us today.